Carisma Therapeutics - About the company
Carisma Therapeutics is a public company based in Philadelphia (United States), founded in 2016. It operates as a Developer of chimeric antigen receptor macrophages for the treatment of cancer. Carisma Therapeutics has raised an undisclosed amount in funding from investors like AbbVie, Symbiosis and Pictet Group. The company has 3419 active competitors, including 1141 funded and 788 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of chimeric antigen receptor macrophages for the treatment of cancer. The company has genetically engineering patient macrophages to create chimeric antigen receptor macrophages (CARMA). The company is focussing on solid tumor indications including recurrent ovarian cancer and HER2-overexpressing malignancies.
- Website
- carismatx.com
- Social
- Email ID
- *****@carismatx.com
- Registered Address
- Philadelphia, Pennsylvania
Key Metrics
Founded Year
2016
Location
Philadelphia, United States
Stage
Public
Latest Funding Round
Ranked
516th among 3419 active competitors
Employee Count
15 as on Aug 31, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Carisma Therapeutics
Carisma Therapeutics is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
CARISMA THERAPEUTICS INC CIN: 300993121 , United States, Active | Dec 26, 999 | - | 69 (As on Dec 31, 2024) | - |
Carisma Therapeutics Inc. CIN: 30-0993121 , United States, Active | Apr 12, 2016 | - | 34 (As on Dec 31, 2020) | - |
Carisma Therapeutics's IPO details
Carisma Therapeutics got listed on Feb 10, 2014.
Click here to take a look at Carisma Therapeutics's IPO in detail
Sign up to download Carisma Therapeutics' company profile
Carisma Therapeutics's funding and investors
Carisma Therapeutics has raised funding over 4 rounds. Its first funding round was on Apr 18, 2017. Its latest funding round was a Post IPO round on Sep 22, 2022 for $*****. 8 investors participated in its latest round. Carisma Therapeutics has 18 institutional investors.
Here is the list of recent funding rounds of Carisma Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 22, 2022 | 8340552 | Post IPO | 5006539 | 7444613 | 6305380 | 5382683 |
Jan 05, 2021 | 9678057 | Post IPO | 1683645 | 3238374 | 9662641 | |
Jul 09, 2019 | 6391531 | Post IPO | 2576310 | 1232644 |
Access funding benchmarks and valuations. Sign up today!View details of Carisma Therapeutics's funding rounds and investors
Carisma Therapeutics' founders and board of directors
Founder? Claim ProfileCarisma Therapeutics' employee count trend
Carisma Therapeutics has 15 employees as of Aug 26. Here is Carisma Therapeutics's employee count trend over the years:
Uncover Carisma Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Carisma Therapeutics's Competitors and alternates
Top competitors of Carisma Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Carisma Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
516th |  Carisma Therapeutics 2016, Philadelphia (United States), Public | Developer of chimeric antigen receptor macrophages for the treatment of cancer | - | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Carisma Therapeutics's competitors? Click here to see the top ones
Carisma Therapeutics's Investments and acquisitions
Carisma Therapeutics has made no investments or acquisitions yet.
Reports related to Carisma Therapeutics
Here is the latest report on Carisma Therapeutics's sector:
News related to Carisma Therapeutics
Filter this listMedia has covered Carisma Therapeutics for a total of 2 events in the last 1 year, 1 of them has been about company updates.
•
United Immunity Acquires Macrophage Assets from Carisma TherapeuticsContract Pharma•May 21, 2026•Uniting Immunity, Carisma Therapeutics
•
Carisma Announces Delisting from Nasdaq and SEC DeregistrationPR Newswire•Dec 05, 2025•Carisma Therapeutics
•
Ocugen merger agreement with Carisma terminated due to funding shortfallInvesting•Sep 18, 2025•Ocugen, Carisma Therapeutics
•
Nasdaq Down 1%; Signet Jewelers Earnings Top ViewsBenzinga•Sep 02, 2025•Ocugen, Carisma Therapeutics
•
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, HSON, TTNPGlobeNewswire•Jul 26, 2025•Carisma Therapeutics, Enzo, Hudson Global, Halper Sadeh and 2 others
•
M&A Class Action Firm Investigates Mergers of CARM, GNTY, TSBX, and SAGEPR Newswire•Jul 04, 2025•SAGE Therapeutics, Turnstone Biologics, Guaranty Bank & Trust, Carisma Therapeutics and 1 other
•
Juan Monteverde Investigates Carisma Therapeutics Inc. MergerGlobeNewswire•Jul 01, 2025•Carisma Therapeutics, Monteverde
•
•
•
Halper Sadeh LLC Investigates BASE and CARM on Behalf of ShareholdersPR Newswire•Jun 23, 2025•Halper Sadeh, Couchbase, Carisma Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Carisma Therapeutics
Explore our recently published companies
- Halmblog Music - Accra based, 2022 founded, Unfunded company
- Himsons - Vadodara based, 1988 founded, Unfunded company
- Com2uS Platform Corp - Unfunded company
- Just Print - Unfunded company
- eomii - Unfunded company
- HOLTWORK - Unfunded company
